Nanopharmacology in translational hematology and oncology
about
Design of FLT3 Inhibitor - Gold Nanoparticle Conjugates as Potential Therapeutic Agents for the Treatment of Acute Myeloid Leukemia.In vivo assessment of bone marrow toxicity by gold nanoparticle-based bioconjugates in Crl:CD1(ICR) mice.The Use of Anthracyclines for Therapy of CNS Tumors.The new era of nanotechnology, an alternative to change cancer treatment.Protein dysregulation in graft versus host disease.Fertility preservation in Hodgkin's lymphoma patients that undergo targeted molecular therapies: an important step forward from the chemotherapy era.
P2860
Nanopharmacology in translational hematology and oncology
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Nanopharmacology in translational hematology and oncology
@ast
Nanopharmacology in translational hematology and oncology
@en
type
label
Nanopharmacology in translational hematology and oncology
@ast
Nanopharmacology in translational hematology and oncology
@en
prefLabel
Nanopharmacology in translational hematology and oncology
@ast
Nanopharmacology in translational hematology and oncology
@en
P2093
P2860
P921
P356
P1476
Nanopharmacology in translational hematology and oncology
@en
P2093
Alexandra Irimie
Cornelia Braicu
Ioana Berindan-Neagoe
Lucian Craciun
P2860
P304
P356
10.2147/IJN.S60488
P407
P5008
P577
2014-07-22T00:00:00Z